Skip to content

新闻稿

Illumina在欧洲推出VeriSeq™ NIPT解决方案

基于NGS的解决方案助力欧盟实验室实现快速经济且高度准确的非侵入性产前检测

2017年4月10日,Illumina公司(纳斯达克股票代码:ILMN)今日宣布推出VeriSeq NIPT解决方案,这是一种已通过CE-IVD认证、基于新一代测序(NGS)的非侵入性产前检测(NIPT)方法,包括通过CE-IVD认证的文库制备及分析软件,让欧盟的实验室能够在内部实现高效准确的NIPT。这个自动化的全面解决方案使得实验室能够在大约一天的时间内筛查胎儿的某些染色体异常

信息来源:http://www.businesswire.com/news/home/20170409005007/en/

VeriSeq™ NIPT Solution (图片来源: Business Wire)

只需要用从母体中抽出的单一管血,VeriSeq NIPT解决方案在早至妊娠10周时即可提供胎儿染色体状态的准确信息。这种非侵入性筛查可提供21三体(唐氏综合征)、18三体(Edwards综合征)、13三体(Patau综合征)以及某些性染色体相关疾病的检查结果。由于灵敏度和特异性高(假阳性和假阴性低),基于NGS的NIPT可最大限度地减少侵入性检测程序的需要。

CooperGenomics的业务发展副总裁Tony Gordon博士表示:“作为令人自豪的Illumina合作伙伴,我们很高兴不久后就能使用新的VeriSeq™ NIPT程序来支持我们的NIPT检测。VeriSeq™ NIPT带来的进步能够更快地为我们的临床合作伙伴提供结果,且灵敏度高,检测失败率极低。”

VeriSeq™ NIPT解决方案凭借 Illumina 边合成边测序的双端测序技术,并在流程、仪器和软件中融入创新,使得任何实验室都能接触到基于NGS的NIPT。这个自动化的可靠解决方案提供了试剂、仪器、安装和培训,以及前所未有的快速周转;实验室在大约一天的时间内可处理多达96个样本。为了证明其性能,Illumina 对超过3100个母体样本开展了严格的临床准确性支持研究,它表明VeriSeqNIPT解决方案不仅能提供高度灵敏且特异的21、13和18三体结果,而且能证明报告的性染色体非整倍体高度一致。

at Illumina 生殖遗传健康的副总裁兼总经理Jeff Hawkins说:“VeriSeqNIPT解决方案带来了快速的流程和空前的自动化,彻底改变了NIPT。有了这种通过CE-IVD认证并特有CE-IVD文库制备和分析软件的解决方案,客户如今可在他们自己的实验室中开展非常可靠的、基于NGS的NIPT。利用这个全新的解决方案,实验室有理由相信,他们正为准父母们提供一种高度可靠的技术,可获得准确的结果。”

VeriSeqNIPT解决方案现正接受订单,并开始发售。若有意了解更多信息,请访问: www.illumina.com/VeriSeqNIPTEU

关于Illumina

Illumina公司通过解码基因组而改善人类健康。我们注重创新,这使我们成为DNA测序和芯片技术的全球领导者,并为科研、临床和应用市场的客户提供服务。我们的产品应用在生命科学、肿瘤学、生殖保健、农业及其他新兴市场上。如欲了解更多信息,请访问:www.illumina.com.cn 或关注 @illumina。

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

 

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
ir@illumina.com
or
Media:
David Robertson
+44 (0)1223.824909
pr@illumina.com
or
Tina Amirkiai
858-882-6822
pr@illumina.com

 

Recent Articles

Veterans Find New Rewards at Illumina
Veterans Find New Rewards at Illumina
Opening Doors for Students and the Possibilities of a STEM Career
Opening Doors for Students and the Possibilities of a STEM Career
Let it Grow: A DNA Database for Plants, One Species at a Time
Let it Grow: A DNA Database for Plants, One Species at a Time